A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol

A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol

Abstract Background Small-cell lung cancer (SCLC) accounts for 12–15% of lung cancers and has a limited prognosis, with approximately one-third of SCLC patients having a poor performance status (PS). Patients with extensive-stage (ES) SCLC and a poor PS have a poor prognosis. For this population, ov...

Full description

Bibliographic Details
Main Authors: Tetsuhiko Asao, Satoshi Watanabe, Takahiro Tanaka, Satoshi Morita, Kunihiko Kobayashi
Format: Article
Language:English
Published: BMC 2022-11-01
Series:BMC Cancer
Subjects:
Small-cell lung cancer
Poor performance status
Immune checkpoint inhibitor
Anti-PD-L1
Durvalumab
Online Access:https://doi.org/10.1186/s12885-022-10222-1

Internet

https://doi.org/10.1186/s12885-022-10222-1

Similar Items